Haematological malignancies are a heterogeneous group of diseases with diverse
incidence. In Europe, the median age at diagnosis across all disease entities is 69 years …

Diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable disease and
is most common in older people. Rituximab-CHOP (cyclophosphamide, doxorubicin …

BACKGROUND Chronotherapy is a drug intervention at specific times of the day to optimize
efficacy and minimize adverse effects. Its value in hematologic malignancy remains to be …

Non-Hodgkin lymphoma (NHL) is a disease of older adults, with a median age at diagnosis
of 67 years. Treatment in older adults with NHL is challenging. The aging process is …

Aims There is a lack of therapies able to prevent anthracycline cardiotoxicity (AC). Remote
ischaemic conditioning (RIC) has shown beneficial effects in preclinical models of AC …

Background: The objectives of this study were to determine whether frailty is associated with
survival in a population-based sample of patients with diffuse large B-cell lymphoma …

Large B-cell lymphomas (LBCLs) are a biologically heterogenous group of clinically
aggressive malignancies arising from mature B lymphocytes. Current classification systems …

Introduction The standard of care for diffuse large B-cell lymphoma (DLBCL) is rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, its ideal …

Lymphoma, a malignancy originating from the aberrant proliferation of lymphocytes in the
lymphatic system, becomes one of the prime concerns in health care across the world. The …

Diffuse large B-cell lymphoma (DLBCL) is an aggressive but often curable malignancy.
Older patients, especially those 80 years and older, have poor outcomes compared to …